id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2004-D-0298-0006,FDA,FDA-2004-D-0298,Compliance Policy Guide: Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs; Notice to Extend Expiration Date,Notice,Notice of Availability,2012-12-17T05:00:00Z,2012,12,2012-12-17T05:00:00Z,,2012-12-17T14:58:49Z,2012-30297,0,0,090000648118f615
FDA-2004-D-0298-0005,FDA,FDA-2004-D-0298,Compliance Policy Guides: Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs,Notice,NEC-Notice of Extension,2010-12-23T05:00:00Z,2010,12,2010-12-23T05:00:00Z,,2024-11-07T22:30:10Z,2010-32274,1,0,0900006480bbea44
FDA-2004-D-0298-0004,FDA,FDA-2004-D-0298,Compliance Policy Guide; Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs; Notice to Extend Expiration Date,Notice,NEC-Notice of Extension,2008-12-22T05:00:00Z,2008,12,2008-12-22T05:00:00Z,,2008-12-22T12:52:04Z,E8-30297,0,0,09000064807e6876
FDA-2004-D-0298-0003,FDA,FDA-2004-D-0298,FDA,Notice,NEC-Notice of Extension,2007-11-23T05:00:00Z,2007,11,2007-11-21T05:00:00Z,,2008-04-12T00:35:32Z,,0,0,0900006480472d20
FDA-2004-D-0298-0001,FDA,FDA-2004-D-0298,FDA,Notice,NAD-Notice of Availability of Data,2004-11-19T05:00:00Z,2004,11,2004-11-15T05:00:00Z,2004-11-16T04:59:59Z,2008-04-12T00:35:32Z,,0,0,0900006480472d15
FDA-2004-D-0298-0002,FDA,FDA-2004-D-0298,Guideline,Supporting & Related Material,GDL-Guidance,2004-11-19T05:00:00Z,2004,11,,,2008-04-12T00:35:32Z,,0,0,0900006480472d17